latest news in companies
German Stock Market Hits Record Highs Amid Economic Pressure
Frankfurt, Sunday, 30 August 2026.
Despite persistent headwinds in European manufacturing, Germany’s benchmark DAX reached 26,569.99 points as major financial institutions like Deutsche Bank actively execute large-scale share buybacks to bolster market momentum.
PetroChina Secures Crude Supply and Posts Gains Ahead of Earnings
Beijing, Sunday, 30 August 2026.
PetroChina stock has gained 21.60% year-to-date, recently purchasing 4 million crude barrels from Saudi Aramco despite Hormuz transit disruptions. The energy giant reports key financial earnings on August 31.
Intel Chip Manufacturing Advances Prompt Surge in Customer Demand
Santa Clara, Sunday, 30 August 2026.
Intel reported rapid manufacturing defect drops in its upcoming chip process, beating internal targets and shifting potential customers from evaluating data to actively securing production capacity.
Ares Capital Maintains Dividend Yield Near Ten Percent Amid Shifting Private Credit Markets
New York, Sunday, 30 August 2026.
Business development company Ares Capital offers a 9.63% yield while sustaining a 17-year record of steady distributions, highlighting middle-market loan resilience despite modest quarterly earnings pressure.
Everything Sprouts Expands Sprout Recall After 55 Bacterial Infections Reported Across 15 States
Washington, Saturday, 29 August 2026.
Minneapolis-based Everything Sprouts expanded its August 2026 produce recall to include Robust Radish Mix following a multistate outbreak of E. coli and Salmonella linked to 55 illnesses and four hospitalizations.
Stephen Curry Holds Key to Golden State Warriors' Financial Future
San Francisco, Saturday, 29 August 2026.
As of August 29, 2026, Stephen Curry is eligible for a two-year, $136.7 million extension. His decision directly dictates Golden State’s future salary cap flexibility and free-agent spending power.
Takeda Stock Holds Firm amid New Drug Approvals and Global Market Shifts
Tokyo, Saturday, 29 August 2026.
Takeda Pharmaceutical maintains stable share performance on the Tokyo Stock Exchange, supported by recent U.S. and Japanese regulatory approvals, despite broader net losses and shifting global healthcare demand.